Compare Best Buy Co Inc (BBY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs Recursion Pharmaceuticals Inc — how do they compare? Best Buy Co Inc trades at $82.59 (market cap $17.37B), while Recursion Pharmaceuticals Inc trades at $3.33 (market cap $1.78B). The key difference: Best Buy Co Inc is far larger — about 9.8× Recursion Pharmaceuticals Inc's market cap, and Best Buy Co Inc pays a 4.66% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BBY | RXRX | |
|---|---|---|
Market Cap | $17.37B | $1.78B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.17 | $6.79 |
52-Week Low | $55.52 | $2.84 |
Enterprise Value | $19.75B | $1.30B |
Dividend Yield | 4.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Best Buy (BBY) trades at $82.00, up 2.47% today, with a bearish technical signal and mixed sentiment. Recent earnings beats and a forward P/E of 15.19 suggest reasonable valuation, but revenue has declined from $51.8B in 2022 to $41.5B in 2025. The company is testing smaller store formats and appointed a new CFO in August 2026, aiming to stabilize operations amid leadership changes.
Outlook is cautious; analyst consensus is a Hold with a $81.69 price target. Opportunities include cost control and dividend yield, but risks involve persistent revenue pressure, competitive threats, and execution risks from management turnover. Net cash flow turned positive in 2025, yet margin compression remains a concern for sustained growth.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
